- All-oral, once-daily, chemotherapy-free, fixed-duration ibrutinib plus venetoclax (I+V) combination met its primary endpoint of progression-free survival (PFS) as assessed by an independent review committee (IRC); I+V reduced the risk of disease progression or death by 78% compared to chlorambucil plus obinutuzumab (C+O)
- The safety profile of I+V was generally consistent with the safety profile of the single agents, and tolerability profiles were consistent with CLL treatment in the enrolled patient population
- Data will be presented during the late-breaking abstract session at the European Hematology Association (EHA) 2021 Virtual Congress (Abstract #LB1902)
PR Newswire
NORTH CHICAGO, Ill., June 12, 2021
